AAM reacts to Avalere study on generic drug costsThe Avalere analysis shows that generic drugs continue to be misplaced on higher formulary tiers, unfairly driving up costs for patients. Bausch Health responds to Norwich Pharmaceuticals’ tentative FDA nod for rifaximinXifaxan 200 mg is indicated for travelers' diarrhea and currently contributes less than 1% of Salix’s revenues. Dr. Reddy’s debuts generic Revlimid Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5-mg and 20-mg strengths. Xiromed launches generic Faslodex Generic Faslodex is used to treat advanced-stage, hormone receptor-positive, HER2-negative breast cancer. Alembic intros generic Epiduo Forte Epiduo Forte is indicated for the topical treatment of acne vulgaris in adults and pediatric patients aged 12 years old and older. Dr. Reddy’s, Aurigene Pharmaceutical Services to explore drugs for neglected tropical diseases The parties will work toward ensuring access to drugs at affordable prices to patients in need. Cipla receives FDA confirmation for generic Revlimid Lenalidomide is an immunomodulatory drug indicated for several hematological malignancies in adults. Amneal appoints EVP, chief commercial officer of specialty Amneal has appointed Gustavo Pesquin as executive vice president, chief commercial officer of specialty, effective Sept. 6. Fresenius Kabi’s biosimilar Stimufend obtains FDA OK Stimufend is indicated for the treatment of cancer patients undergoing chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia. Lannett completes clinical trial subject dosing of biosimilar insulin glargine Lannett anticipates launching biosimilar insulin glargine in the first half of 2024. First Previous 75 76 77 78 79 Next Last
